P3.06-003 SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (NSCLC). A UK Randomized Phase III Trial Yenting Ngai,

Slides:

Advertisements

Similar presentations

A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.

Advertisements

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

SC17.02 Lung Cancer in China: Challenges and Perspectives

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

SC09.04 Radiotherapy in China

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

MA12.06 Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis Shaohua Lu, Takashi.

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

P The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC) Nicholas Faris, Meredith.

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

MA13.01 Markerless Tumor Tracking during Lung Radiotherapy Using Intrafraction X- Ray Imaging Chun-Chien (Andy) Shieh, Vincent Caillet, Michelle Dunbar,

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

P Risk Stratification Model to Predict Survival Following Surgical Resection for Lung Cancer Using Pathological Variables Timothy Edwards, Charlene.

George Blumenschein, MD, John V. Heymach, MD, PhD

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC) Taofeek Owonikoko,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

P Molecular Characterization of Non-Small Cell Lung Cancers (NSCLC) in Young Patients from an Argentine Population V. Denninghoff, G. Recondo,

P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153 David Spigel,

P Phase 1/2 Trial of WT1 TCR-Transduced Central Memory and Naïve CD8+T Cells for Patients with Mesothelioma and Non-Small Cell Lung Cancer Sylvia.

P3.02b-125 Failure to Tyrosine Kinase Inhibitors and Patterns of Progression in Patients with Advanced Non-Small Cell Lung Cancer Feliciano Barron, Laura-Alejandra.

P3.02b-075 Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients Tao Jiang, Shengxiang.

P3.02b-062 Safety of Necitumumab and Abemaciclib Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Benjamin Besse, Johan.

P Predictors of Survival after Whole Brain Radiotherapy for Patients with Brain Metastasized Lung Cancer Georgios Tsakonas, Fatou Hellman, Signe.

PS02.17 A Biomarker-Driven Algorithm for Sequencing of Systemic Therapy for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Survey of 25 Investigators

ED11.01 Systemic Therapy for Advanced Oncogene-Driven NSCLC

P3.02b-061 A Phase II Study of Nab-Paclitaxel (Nab-P) in Patients with Advanced Non- Small Cell Lung Cancer (NSCLC) with EGFR Mutations Christina Baik,

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Journal of Thoracic Oncology

Heidi B. Rolke, Frode Gallefoss Journal of Thoracic Oncology

P Accuracy of Combined Semantic and Computational CT Features in Predicting Non-Small Cell Lung Cancer Subtype Usman Bashir, Andrea Bille, Levon.

JCSE01.16 Positive Correlation Between Whole Genomic Copy Number Variant Scoring and the Grading System in Lung Non-Mucinous Invasive Adenocarcinoma

PD5-1-7: Time trends in nodal CT volume and nodal motion during radiotherapy for patients with stage III non-small cell lung cancer Geert Bosmans, Angela.

P Assessment of Lung Tumor Motion Comparing 4DCT, 4DCBCT and Motion of Implanted Beacons during Imaging and Irradiation Elisabeth Steiner, Chun-Chien.

ES Lung Cancer Surgery for High Risk Patients

P Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Nicola.

A1-02: A need to standardize post-operative radiotherapy (PORT) fields used for non- small cell lung cancer (NSCLC): analysis of an international dummy-run.

MTP13-01: Indications and limitations of bronchoscopy

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

MA Comparison of EORTC, PERCIST, PeterMac & Deauville PET Response Criteria after Radical ChemoRT in Non-Small-Cell Lung Cancer G. Turgeon, A.

P3.02a-023 Treatment Patterns and Early Outcomes of ALK+ Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study Edmond Bendaly,

A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.

M. Kusumoto Journal of Thoracic Oncology

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced,

P Impact of Systematic EBUS-TBNA Mediastinal Staging on Radical Radiotherapy Planning in NSCLC N. Hardcastle, A. Cole, G. Turgeon, R. Thomas,

European Lung Cancer Conference (ELCC) 2016 Organisation

OA Video-Assisted Thoracoscopic Surgery vs

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

P2.03b-002 Efficacy and Safety of WBRT Combined with Endostar in Patients with Advanced Non-Small Cell Lung Cancer Xiaorong Dong, Ruiguang Zhang, Xican.

PS01.07 The Clinical Necessity of Extended Thymectomy for Thymic Squamous Cell Carcinomas Revealed by Exome Sequencing J. Jiang, Y. Zhang, C. Jin, J.

3A.01 Efficacy of Programmatic Combined Stereotactic Ablative Radiotherapy and Anti- PD-1 Therapy in Advanced Lung Cancer: A Retrospective Analysis A.

IASLC 6th Latin American Conference on Lung Cancer

P Clinical Consequences, Quality of Life, and Management of Neutropenic NSCLC Patients in the REVEL Trial D. Ettinger, O. Arrieta, N. Karaseva,

OA Survival Trends Among Non-Small Cell Lung Cancer (NSCLC) Patients Over A Decade: Impact of Initial Therapy at Academic Centers B. Dholaria,

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

M. Pasquinelli, Z. Deliu, D. Rosenberg, C. Weldon, S. Obilade, A

Journal of Thoracic Oncology

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

P1. 02: Lung Cancer - A Previously Years Survival Study

A Review of First-Line Treatment for Small-cell Lung Cancer

Mark A. Socinski, MD Journal of Thoracic Oncology

MA01.03 The Non-Invasive LuCED® Test for Detection of Early Stage Lung Cancer Michael Meyer, Timothy Bell, Daniel Sussman, David Wilbur, Chris Presley,

Robert Comis, MD, The Passing of a “Lung Man”

ED04.01 Surgery in Bronchopulmonary Typical and Atypical Carcinoids

Presentation transcript:

P3.06-003 SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (NSCLC). A UK Randomized Phase III Trial Yenting Ngai, Gerard Hanna, John Conibear, Nicholas Counsell, Laura Hughes, Laura Farrelly, David Landau Journal of Thoracic Oncology Volume 12, Issue 1, Pages S1425-S1426 (January 2017) DOI: 10.1016/j.jtho.2016.11.2185 Copyright © 2016 Terms and Conditions

Journal of Thoracic Oncology 2017 12, S1425-S1426DOI: (10.1016/j.jtho.2016.11.2185) Copyright © 2016 Terms and Conditions